Cabaletta Bio, Inc. (CABA) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Cabaletta Bio (CABA) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Cabaletta is a clinical-stage biotech building CD19-directed CAR-T cell therapies that aim to reset the immune system in autoimmune diseases, led by rese-cel (also called CABA-201). It is pre-revenue and burns cash, so the thesis rests entirely on clinical trial readouts, and the biggest risk is that an early-stage program disappoints, gets delayed, or runs out of funding before reaching the market. As of October 16, 2026 the stock closed at about $1.46, its 52-week low, for a market value near $248 million, down roughly 43% in the past month and 34% year to date. This is a highly speculative, binary-outcome stock.

CABA stock price

As of 2026-11-16, Cabaletta Bio, Inc. (CABA) last closed at $1.11, down 53.6% over the past year. Over the past 52 weeks it has traded between $1.11 and $4.15.

CABA last close
$1.11
1 day
-13.28%
1 month
-21.28%
1 year
-53.56%
52-week range
$1.11 to $4.15
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Cabaletta Bio, Inc.'s investor relations page. Walnut is informational, not investment advice.

CABA key stats

At $1.11 on November 16, 2026, Cabaletta Bio, Inc. (CABA) has a market cap of $239M.

Market cap
$239M
Price to book
0.8
Beta
3.54

Market cap, P/E and yield are measured at the $1.11 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Cabaletta Bio, Inc. (CABA)?

The last two weeks for Cabaletta Bio, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • CABA closed at $1.11 on November 16, 2026, down 26.0% over the past five trading days (from $1.50).
  • On November 9, 2026, Cabaletta Bio, Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) and other events (Item 7.01, Item 8.01). Read the 8-K on sec.gov
  • On November 5, 2026, Cabaletta Bio, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, Cabaletta Bio, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 9, 2026, Citigroup lowered its target to $8.00 from $10.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Cabaletta Bio, Inc. (CABA) do?

Cabaletta Bio, Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune disease. Its CABA (Cabaletta Approach to B cell Ablation) platform pursues the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach, which uses CD19-directed CAR-T cells to deplete the B cells that drive autoimmune conditions, with the goal of a temporary but complete "immune system reset" rather than chronic suppression. The lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-CAR T cell therapy.

Rese-cel is being studied in the RESET (REstoring SElf-Tolerance) Phase 1/2 clinical program across multiple indications, including systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta has built a footprint of active US clinical sites with planned expansion, and has worked with the FDA on potential registrational trial designs. The company is pre-revenue, funds itself through equity raises, and has reported early clinical responses in some treated patients while emphasizing that the data remain early.

The financial picture shifted in 2026. After a roughly $150 million registered direct offering in May, Cabaletta reported about $225 million of cash at the end of June, and then collected about $115 million more between July and mid-September as holders exercised warrants from its June 2025 offering at $2.50 per share before they expired on September 12 (about $128 million in total from those warrants). Second-quarter results, reported in August, showed a loss of $0.34 per share, in line with estimates, and the trailing net loss is about $181 million. The share price moved the other way: CABA closed at about $1.46 on October 16, 2026, down about 43% in a month, 48% in three months, 34% year to date and 49% over the past year, giving a market value of roughly $248 million.

What's driving Cabaletta Bio, Inc. (CABA)?

Platform aimed at a large autoimmune market

Cabaletta is applying CD19 CAR-T, a modality already validated in blood cancers, to autoimmune diseases that today are managed with chronic immunosuppression. If the "immune reset" thesis holds across several indications, the addressable population is broad. Whether that translates into approved products depends on data that does not yet exist at registrational scale.

Multi-indication RESET program

Rather than betting on a single disease, the RESET Phase 1/2 program spans lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. This diversification means more shots on goal, but also more trials to fund and execute, and early responses in a handful of patients are not the same as controlled, durable efficacy.

Early clinical signals reported

The company has described responses or emerging responses in some patients treated with its CD19 CAR-T approach, and has engaged the FDA on potential registrational paths. These are encouraging directional signals for a clinical-stage biotech, but interpretation is limited by small numbers, short follow-up, and the absence of large randomized data. The sharp fall in the share price through September and October 2026 suggests the market is placing little value on those signals for now.

Capital-dependent and dilution-prone

As a pre-revenue developer, Cabaletta funds operations through equity: a sizeable May 2026 offering (about $141 million net) and roughly $128 million of gross proceeds from warrant exercises, $115 million of it arriving between July and the September 12, 2026 expiry. The earlier stated runway into mid-2027 was given before the warrant cash came in, and the next update is expected with third-quarter results around November 16, 2026. Each round of new shares dilutes existing holders, so access to capital on acceptable terms is part of the investment outcome, not just the science.

What are the risks to Cabaletta Bio, Inc. (CABA)?

CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. The company has reported a going-concern consideration and relies on repeated equity raises and warrant exercises that dilute shareholders; tens of millions of new shares were issued in 2026 alone. Operating cash burn is running at roughly $154 million a year and the trailing net loss is about $181 million. It also competes in a crowded autoimmune cell-therapy field where rivals such as Kyverna are further along toward a first approval, which could affect positioning even if rese-cel succeeds. The stock fell about 43% in the month to October 16, 2026 to a 52-week low near $1.46, which shows how quickly sentiment can turn, and a single negative data point or financing setback can move it sharply again.

What is the Cabaletta Bio, Inc. (CABA) forecast?

8 analysts publish price targets on CABA, averaging $11.75 as of November 2026, or +958.6% against the $1.11 share price on November 16, 2026. The published targets run from $3.00 to $20.00, a wide spread, and the ratings split 8 buy, 2 hold, 0 sell. Over the last six months there have been 0 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CABA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is CABA a buy or a sell?

We give no verdict on Cabaletta Bio, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Platform aimed at a large autoimmune market. Cabaletta is applying CD19 CAR-T, a modality already validated in blood cancers, to autoimmune diseases that today are managed with chronic immunosuppression. The most optimistic published target, $20.00, assumes this works close to its best case.

The case against. CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. The most pessimistic target, $3.00, is roughly what CABA is worth if this bites instead.

Read the full bull and bear case on CABA, including what would have to change to break either one. Walnut is not an investment adviser.

Has Cabaletta Bio, Inc. (CABA) split its stock?

No. Cabaletta Bio, Inc. (CABA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Cabaletta Bio, Inc. (CABA) valued?

Market cap, P/E and dividend yield at today's price are in the CABA key stats above. The business figures below come from Cabaletta Bio, Inc.'s reported results as of October 2026 and change when it next reports.

  • Cash and debt: ~$225 million cash at June 30, 2026, against ~$26 million debt
  • Warrant proceeds: ~$115 million received July 1 to September 12, 2026 (~$128 million total from June 2025 warrants)
  • Net loss (TTM): ~$181 million; Q2 2026 EPS -$0.34, in line with estimates
  • 2026 financing: ~$150 million registered direct offering closed May 2026 (~$141 million net proceeds)
  • Analyst view: Average price target ~$13.25 across 8 analysts

As of October 2026: Cabaletta is pre-revenue, so price-to-earnings does not apply; it trades at about 1.2 times book value. With roughly $225 million of cash at the end of June plus about $115 million of warrant proceeds received since, the ~$248 million market value implies the market is assigning little or no value to the rese-cel pipeline itself. Management has noted going-concern considerations, and third-quarter results, expected around November 16, 2026 with consensus at a loss of $0.31 per share, should update cash and runway.

Who competes with Cabaletta Bio, Inc. (CABA)?

Autoimmune CAR-T developers

Other companies developing engineered cell therapies for autoimmune disease, including Kyverna Therapeutics (widely viewed as furthest along, advancing miv-cel toward a potential first US filing) and Cartesian Therapeutics. These are Cabaletta's most direct comparables, and relative trial timing and data can shape how the market values each.

Large-cap and partnered cell-therapy programs

Bigger players and partnerships are pushing CD19-directed or related cell therapies into autoimmune indications, including Bristol Myers Squibb, AstraZeneca with Gracell, and Autolus Therapeutics. Their scale, manufacturing capacity, and capital can be a competitive challenge for a small clinical-stage company.

Next-generation and in vivo approaches

Newer modalities aim to deliver CD19-directed therapy without the complex manufacturing of autologous CAR-T, including in vivo approaches from companies such as Aera. If these prove safer or simpler at scale, they could pressure the economics of traditional engineered-cell therapies across the field.

Established autoimmune drug makers

Even if cell therapy works, it competes with entrenched biologics and immunosuppressants from large pharmaceutical companies that already treat lupus, myositis, and related diseases. Adoption depends on cell therapy showing meaningfully better or more durable outcomes than these existing standards of care.

What stocks are similar to Cabaletta Bio, Inc. (CABA)?

Other names that sit close to CABA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Cabaletta Bio, Inc. (CABA)

There are three common ways to get CABA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CABA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CABA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Cabaletta Bio, Inc. (CABA)

If you believe that CD19-directed CAR-T therapy can durably reset the immune system in autoimmune diseases like lupus, myositis, and systemic sclerosis, and that Cabaletta's rese-cel program can convert early signals into registrational data, then CABA is one way to express that view. It is a clinical-stage, pre-revenue company whose value is tied to trial outcomes, regulatory decisions, and continued access to capital rather than current earnings. In 2026 it raised money twice, through a May offering and about $128 million of warrant exercises, while the share price fell to about $1.46 by mid-October, so the market is valuing it at little more than its cash. The stock can move sharply on single data points, and the company itself has flagged going-concern considerations, so position sizing and time horizon matter as much as the science. None of this is a suggestion to buy or sell it.

More on Cabaletta Bio, Inc. (CABA)

Whether CABA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CABA a buy or a sell?, and where the stock could go from here in the CABA stock forecast.

For income investors, whether CABA pays a dividend and how the payout looks is covered in does CABA pay a dividend? And to weigh CABA against a peer, read the full side-by-side comparisons: CABA vs CAR and CABA vs BMY.

Wondering how CABA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Cabaletta Bio, Inc.

Ask Walnut's AI anything about CABA and see how it fits what you own.

FAQ

Is CABA a good stock to buy right now?

+

That depends on your risk tolerance, and this is not advice. The bull view is that CD19 CAR-T could reset the immune system across several large autoimmune markets, rese-cel has shown early signals, and at about $248 million the market value in October 2026 sits close to the company's cash. The bear view is that CABA is pre-revenue, burns cash, faces going-concern considerations and ongoing dilution, has fallen about 49% over the past year, and trails rivals like Kyverna toward a first approval. It is a binary, speculative stock.

What does Cabaletta Bio do?

+

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases. Its CABA platform uses CD19-directed CAR-T cells to deplete the B cells that drive conditions such as lupus, myositis, and systemic sclerosis, aiming for a temporary but complete immune reset. Its lead candidate, rese-cel, is in the RESET Phase 1/2 program. It does not yet sell any approved products.

Is CABA profitable?

+

No. Cabaletta is a pre-revenue, clinical-stage biotech that spends heavily on research and development and reports consistent net losses: about $168 million in 2025, about $43.5 million in the first quarter of 2026, a loss of $0.34 per share in the second quarter, and about $181 million over the trailing twelve months. It had an accumulated deficit of around $560.5 million at the end of March 2026 and has flagged going-concern considerations. Profitability would require an approved, commercialized product, which the company does not yet have.

Does CABA pay a dividend?

+

No. Cabaletta Bio does not pay a dividend. Like most clinical-stage biotechnology companies, it reinvests all of its capital into research, clinical trials, and operations rather than returning cash to shareholders. Pre-revenue developers that are still funding trials through equity raises generally do not pay dividends, and there is no indication that Cabaletta plans to.

What is rese-cel and the CABA platform?

+

Rese-cel (resecabtagene autoleucel, formerly CABA-201) is Cabaletta's lead candidate, a fully human CD19-directed CAR-T cell therapy. The CABA platform, short for Cabaletta Approach to B cell Ablation, engineers a patient's T cells to deplete the B cells that drive autoimmune disease. The goal is a temporary but complete immune system reset rather than the chronic suppression used by many existing treatments.

How can I buy Cabaletta Bio (CABA) stock?

+

CABA trades on the Nasdaq, so you can buy shares or fractional shares through any major brokerage account, the same way you would buy any listed stock. Some biotech or small-cap ETFs may also hold it as part of a basket. With Walnut you can hold CABA as one position inside a thematic basket alongside other names that fit your investing thesis. Walnut is not an investment adviser.

Why is CABA stock so volatile?

+

CABA is a small, clinical-stage biotech with no product revenue, so its price is driven largely by expectations around clinical trial data, regulatory updates, and financing rather than earnings. Single readouts can move the stock sharply in either direction, and in the month to October 16, 2026 it fell about 43% to a 52-week low near $1.46. Equity raises and warrant exercises can dilute holders, and competitive news from rivals can also swing sentiment. This binary, news-driven profile makes it inherently volatile.

Who competes with Cabaletta Bio in autoimmune cell therapy?

+

Cabaletta competes with other autoimmune CAR-T developers such as Kyverna Therapeutics, often seen as furthest along, and Cartesian Therapeutics, plus larger or partnered efforts from Bristol Myers Squibb, AstraZeneca with Gracell, and Autolus. Newer in vivo approaches from companies like Aera, and established biologics from large pharmaceutical firms, are also part of the competitive picture.

How much cash does Cabaletta have?

+

Cabaletta reported about $225 million of cash at June 30, 2026, against about $26 million of debt. Between July 1 and September 12, 2026, warrant holders from the June 2025 offering exercised about 46 million warrants at $2.50 per share, adding about $115 million of gross proceeds. The company's earlier runway guidance (into mid-2027) predates that cash, so the third-quarter report around November 16, 2026 is the next point at which a refreshed runway would normally appear.

How has CABA stock performed in 2026?

+

As of the October 16, 2026 close near $1.46, CABA was down about 34% year to date, 48% over three months, 43% over one month and 49% over the past year, finishing at the bottom of its 52-week range of about $1.46 to $4.23. Analysts' average price target of about $13.25 sits far above that, which mostly reflects how wide the range of outcomes is for a clinical-stage company. Past performance does not predict future returns.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Cabaletta Bio, Inc.'s investor relations page or your broker before making investment decisions.